NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with ...
tylerpaper.com
news
2022-10-17 11:32:41

Trial did not meet primary endpoint of statistically significant rate of change in GA lesion area using slope analysis over 52 weeks for NGM621 versus shamNGM621 showed favorable safety and tolerability, with no evidence of increased CNV conversion and no treatment-related SAEsAdditional analyses to be presented in early November at The Retina Society Annual Scientific MeetingNGM Bio to host conference call and webcast today at 8:00 a.m. ETSOUTH SAN FRANCISCO, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc.
